These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 2061900)

  • 1. Spontaneous adverse drug reaction reporting vs event monitoring: a comparison.
    Fletcher AP
    J R Soc Med; 1991 Jun; 84(6):341-4. PubMed ID: 2061900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A distributed, collaborative intelligent agent system approach for proactive postmarketing drug safety surveillance.
    Ji Y; Ying H; Farber MS; Yen J; Dews P; Miller RE; Massanari RM
    IEEE Trans Inf Technol Biomed; 2010 May; 14(3):826-37. PubMed ID: 20007038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Safety of medicinal products and reporting of adverse drug reactions].
    Skibicka I; Maciejczyk A
    Neurol Neurochir Pol; 2004; 38(6):503-10. PubMed ID: 15654675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients' role in reporting adverse drug reactions.
    van Grootheest K; de Jong-van den Berg L
    Expert Opin Drug Saf; 2004 Jul; 3(4):363-8. PubMed ID: 15268652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outliers and patients with adverse drug reactions.
    Edwards IR
    Drug Saf; 2009; 32(8):623-4. PubMed ID: 19591527
    [No Abstract]   [Full Text] [Related]  

  • 6. Discovery of adverse drug reactions. A comparison of selected phase IV studies with spontaneous reporting methods.
    Rossi AC; Knapp DE; Anello C; O'Neill RT; Graham CF; Mendelis PS; Stanley GR
    JAMA; 1983 Apr 22-29; 249(16):2226-28. PubMed ID: 6834622
    [No Abstract]   [Full Text] [Related]  

  • 7. The monitoring medicines project: a multinational pharmacovigilance and public health project.
    Pal SN; Olsson S; Brown EG
    Drug Saf; 2015 Apr; 38(4):319-28. PubMed ID: 25829215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can Disproportionality Analysis of Post-marketing Case Reports be Used for Comparison of Drug Safety Profiles?
    Michel C; Scosyrev E; Petrin M; Schmouder R
    Clin Drug Investig; 2017 May; 37(5):415-422. PubMed ID: 28224371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse event detection in drug development: recommendations and obligations beyond phase 3.
    Berlin JA; Glasser SC; Ellenberg SS
    Am J Public Health; 2008 Aug; 98(8):1366-71. PubMed ID: 18556607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring the FDA adverse event reporting system to generate hypotheses for monitoring of disease characteristics.
    Fang H; Su Z; Wang Y; Miller A; Liu Z; Howard PC; Tong W; Lin SM
    Clin Pharmacol Ther; 2014 May; 95(5):496-8. PubMed ID: 24448476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ["Re-evaluation upon suspected event" is an approach for post-marketing clinical study: lessons from adverse drug events related to Bupleuri Radix preparations].
    Wu SX; Sun HF; Yang XH; Long HZ; Ye ZG; Ji SL; Zhang L
    Zhongguo Zhong Yao Za Zhi; 2014 Aug; 39(15):2983-8. PubMed ID: 25423845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Veterinary pharmacovigilance in India: A need of hour.
    Kumar R; Kalaiselvan V; Verma R; Kaur I; Kumar P; Singh GN
    Indian J Pharmacol; 2017; 49(1):2-3. PubMed ID: 28458414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting adverse drug events from personal health messages.
    Chee BW; Berlin R; Schatz B
    AMIA Annu Symp Proc; 2011; 2011():217-26. PubMed ID: 22195073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A reference standard for evaluation of methods for drug safety signal detection using electronic healthcare record databases.
    Coloma PM; Avillach P; Salvo F; Schuemie MJ; Ferrajolo C; Pariente A; Fourrier-Réglat A; Molokhia M; Patadia V; van der Lei J; Sturkenboom M; Trifirò G
    Drug Saf; 2013 Jan; 36(1):13-23. PubMed ID: 23315292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility and Educational Value of a Student-Run Pharmacovigilance Programme: A Prospective Cohort Study.
    Schutte T; Tichelaar J; Reumerman MO; van Eekeren R; Rolfes L; van Puijenbroek EP; Richir MC; van Agtmael MA
    Drug Saf; 2017 May; 40(5):409-418. PubMed ID: 28120270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An MCEM Framework for Drug Safety Signal Detection and Combination from Heterogeneous Real World Evidence.
    Xiao C; Li Y; Baytas IM; Zhou J; Wang F
    Sci Rep; 2018 Jan; 8(1):1806. PubMed ID: 29379048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring drug safety in Astrakhan, Russia.
    Kirilochev OO; Dorfman IP; Umerova AR
    Int J Risk Saf Med; 2015; 27 Suppl 1():S33-4. PubMed ID: 26639700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postmarketing surveillance of adverse drug reactions: problems and solutions.
    Lortie FM
    CMAJ; 1986 Jul; 135(1):27-32. PubMed ID: 3719483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of Adverse Drug Reactions using Medical Named Entities on Twitter.
    MacKinlay A; Aamer H; Yepes AJ
    AMIA Annu Symp Proc; 2017; 2017():1215-1224. PubMed ID: 29854190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse drug reaction or innocent bystander? A systematic comparison of statistical discovery methods for spontaneous reporting systems.
    Dijkstra L; Garling M; Foraita R; Pigeot I
    Pharmacoepidemiol Drug Saf; 2020 Apr; 29(4):396-403. PubMed ID: 32092786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.